Incyte INCY OPZELURA — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's opzelura — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's OPZELURA — total revenues?
- Incyte (INCY) reported OPZELURA — total revenues of $143.02M in Q1 2026.
- How has Incyte's OPZELURA — total revenues changed year-over-year?
- Incyte's OPZELURA — total revenues increased by 20.5% year-over-year, from $118.71M to $143.02M.
- What is the long-term trend for Incyte's OPZELURA — total revenues?
- Over 3 years (2022 to 2025), Incyte's OPZELURA — total revenues has grown at a 74.0% compound annual growth rate (CAGR), from $128.74M to $678.46M.
- What does OPZELURA — total revenues mean?
- This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic brand within the company's portfolio. It captures the market adoption and commercial performance of the drug, reflecting both volume and pricing dynamics across its approved indications. This figure is a critical indicator of the product's lifecycle stage and its contribution to the company's overall top-line growth.